|Bid||5,036.90 x 0|
|Ask||0.00 x 0|
|Day's Range||4,985.00 - 5,105.35|
|52 Week Range||2,495.05 - 5,512.65|
|Beta (5Y Monthly)||0.00|
|PE Ratio (TTM)||54.49|
|Earnings Date||May 10, 2018 - May 14, 2018|
|Forward Dividend & Yield||25.00 (0.49%)|
|Ex-Dividend Date||Jul 13, 2020|
|1y Target Est||2,587.45|
Dr. Reddy's (RDY) receives approval from the DCGI to conduct a phase III study on the Sputnik V vaccine for the treatment of COVID-19 in India.
Dr. Reddy’s Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) announced today that it has received approval from the Drugs Control General of India (DCGI) to conduct phase 3 clinical trial for the Sputnik V vaccine in India.
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that the independent Data and Safety Monitoring Board (DSMB) has reviewed the safety data from the phase 2 clinical trial of the Sputnik V vaccine and recommended the phase 3 recruitment and continue the clinical trial without any modifications.